2006
DOI: 10.1016/j.amjcard.2006.01.049
|View full text |Cite
|
Sign up to set email alerts
|

Sirolimus-Eluting Stents at Two Years: A Pooled Analysis of SIRIUS, E-SIRIUS, and C-SIRIUS With Emphasis on Late Revascularizations and Stent Thromboses

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

4
24
2
3

Year Published

2007
2007
2016
2016

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 79 publications
(33 citation statements)
references
References 20 publications
4
24
2
3
Order By: Relevance
“…This contrasts with observations in porcine models, in which the initial benefits of DES are reported to disappear with time, 18 but mirrors long-term findings of the first DES trials 15,16,19 and the 2-year results of the RESEARCH registry. 11 As evident in Figure 1, the advantage of DES over BMS is largely obtained during the first year and then maintained without apparent loss of efficacy over time; however, the 46% reduction of target-lesion revascularization and the 32% reduction of TVR does not appear as striking as reported in clinical trials.…”
Section: Discussioncontrasting
confidence: 53%
“…This contrasts with observations in porcine models, in which the initial benefits of DES are reported to disappear with time, 18 but mirrors long-term findings of the first DES trials 15,16,19 and the 2-year results of the RESEARCH registry. 11 As evident in Figure 1, the advantage of DES over BMS is largely obtained during the first year and then maintained without apparent loss of efficacy over time; however, the 46% reduction of target-lesion revascularization and the 32% reduction of TVR does not appear as striking as reported in clinical trials.…”
Section: Discussioncontrasting
confidence: 53%
“…(4) The risk of ST after discontinuation of thienopyridine treatment after 6 months, if present, appears to be small. A cumulative 1.9% incidence of ST at 18 months is higher than that reported in the major randomized trials [25][26][27] or in large registries such as e-Cypher. 16 However, considering the longer follow-up, the rate of ST in the present study is comparable to other studies analyzing "real-world" populations.…”
Section: Discussionmentioning
confidence: 63%
“…This calls into question the temporal and causal link between discontinuation and thrombosis after 6 months, and this finding is in agreement with a recent small study. 29 In many pivotal studies and in some registries, 16,26 the relationship between discontinuation of clopidogrel and development of late ST is not clear. We prefer not to speculate about possible mechanisms for ST that occurs after 6 months or about the benefits of extended dual-antiplatelet therapy.…”
Section: Discussionmentioning
confidence: 99%
“…7,8 Follow-up data from SIRIUS, and other recent trials appeared to alleviate these concerns. 9,10 Since the presentation of these findings, however, the concerns regarding these agents enhancing in stent thrombosis resurfaced. An observational study demonstrated a 30% incidence of in stent thrombosis associated with DES and clopidogrel noncompliance.…”
mentioning
confidence: 99%